Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soluble PD-L1 as predictor of response to nivolumab in metastatic renal cell carcinoma
jRCTs051180092Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC), sponsored by Ono Pharmaceutical. Primary endpoint: progression-free survival. Started May 2018; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on jRCTs051180092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180092.